Compare Merck & Co., Inc. (MRK) vs US Bancorp (USB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs US Bancorp — how do they compare? Merck & Co., Inc. trades at $146.34 (market cap $351.28B), while US Bancorp trades at $57.22 (market cap $88.86B). The key difference: Merck & Co., Inc. is far larger — about 4× US Bancorp's market cap, and US Bancorp pays the higher dividend (3.79%). Which is the better fit depends on your goals — on Pluang, investors hold Merck & Co., Inc. for 98 Days and US Bancorp for 97 Days on average.
| MRK | USB | |
|---|---|---|
Market Cap | $351.28B | $88.86B |
Volume | 7,969,665 | 8,869,993 |
Sector | Health | Financials |
52-Week High | $156.43 | $65.42 |
52-Week Low | $82.49 | $45.28 |
Typical Hold Time | 98 Days | 97 Days |
Enterprise Value | $398.04B | $118.35B |
Dividend Yield | 2.39% | 3.79% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $144.96, up 1.52% today, with a bearish technical signal despite recent earnings beats. The stock shows strong profitability with a 72.97% gross margin and 28.07% net income margin for 2025, though its P/E ratio of 113.9 indicates high valuation. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives amid competitive pressures.
The outlook is mixed: analyst consensus is bullish with a $158.78 price target, but technical indicators and a high P/E suggest near-term caution. Key risks include integration challenges from acquisitions and macroeconomic headwinds affecting pharmaceutical R&D investment. Revenue growth and pipeline execution remain critical for sustained upside.
U.S. Bancorp (USB) trades at $56.81, up 1.14% today, but technical indicators are bearish with moving averages signaling a downtrend. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Fundamentals show strong profitability with a 27.61% net income margin and a modest P/E of 11.38. The company recently raised its dividend by 3.8% to $0.54 per share, reflecting confidence in its financial health.
The outlook is mixed: analyst consensus is bullish with a $69.94 price target, but near-term technical weakness and macroeconomic sensitivity pose risks. Upside potential hinges on continued earnings outperformance and stable interest rates, while downside risks include regulatory changes and economic volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About US Bancorp
As a diversified financial-services provider, U.S. Bancorp is one of the nation's largest regional banks, with branches in well over 20 states, primarily in the Western and Midwestern United States. The bank offers many services, including retail banking, commercial banking, trust and wealth services, credit cards, mortgages, and other payments capabilities.
Read more on USB →
